Prognostic Score-Based Stratification Analysis Reveals Universal Benefits of Radiotherapy on Lowering the Risk of Ipsilateral Breast Event for Ductal Carcinoma In Situ Patients with Different Risk Levels

Overview

Journal Ann Surg Oncol

Publisher Springer

Specialty Oncology

Date 2020 Aug 15

PMID 32794031

Citations 3

Authors

Libo Yang

Dongli Lu

Yutian Lai

Mengjia Shen

Qiuxiao Yu

Ting Lei

Tianjie Pu

Hong Bu

Affiliations

Soon will be listed here.

Abstract

Background: We aimed to analyze the effects of radiotherapy (RT) on the incidence rate of ipsilateral breast event (IBE) in ductal carcinoma in situ (DCIS) patients with lumpectomy after being stratified by prognostic score.

Methods: We identified DCIS patients who received lumpectomy, from the Surveillance, Epidemiology, and End Results (SEER) database from 1988 to 2015. Cumulative incidence functions for competing risk were used to evaluate the effects of RT on IBE risk over time. Three multivariate regression models (weighted, non-weighted, and Fine-Gray) were applied to compare the IBE risk between the RT and non-RT groups after stratifying patients by prognostic score.

Results: Overall, 72,623 DCIS patients were identified from the SEER database and 49,206 (66.8%) patients received RT. During the follow-up period (ranging from 7 to 347 months), the cumulative probability of invasive and in situ IBE was significantly lower in the RT group than in the non-RT group (p < 0.001). After being stratified by prognostic score, the weighted IBE incidence rate increased as the risk level increased (p < 0.050). In multivariate regression models, RT lowered the IBE incidence rate by at least 30% in low-, moderate-, and high-risk DCIS (p < 0.010). In particular, the in situ and invasive IBE incidence rate decreased by over 50% in low-risk DCIS with RT (p < 0.001).

Conclusions: RT is associated with a lowered IBE incidence rate in DCIS patients, regardless of the assigned risk levels for patients. The significant reduction in the IBE incidence rate in low-risk DCIS patients also indicates the potential benefits for recommending RT to such a patient population in clinical practice.

Citing Articles

Molecular subtyping reveals uniqueness of prognosis in breast ductal carcinoma in situ patients with lumpectomy.

Yang L, Shen M, Qiu Y, Tang T, Bu H Breast. 2022; 64:1-6.

PMID: 35462343 PMC: 9039875. DOI: 10.1016/j.breast.2022.03.019.

Incidence, prognosis and nomograms of breast cancer with bone metastases at initial diagnosis: a large population-based study.

Yao Y, Zheng X, Luo X, Wu A Am J Transl Res. 2021; 13(9):10248-10261.

PMID: 34650694 PMC: 8507056.

ASO Author Reflections: Oncologic Outcome of Endoscopic-Assisted Breast Surgery Compared with the Conventional Approach in Breast Cancers.

Lai H Ann Surg Oncol. 2021; 28(12):7381-7382.

PMID: 33907922 DOI: 10.1245/s10434-021-10011-3.

References

Elshof L, Schaapveld M, Rutgers E, Schmidt M, de Munck L, van Leeuwen F . The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study. Breast Cancer Res. 2017; 19(1):26. PMC: 5343406. DOI: 10.1186/s13058-017-0819-4. View

Olivotto I, Bancej C, Goel V, Snider J, McAuley R, Irvine B . Waiting times from abnormal breast screen to diagnosis in 7 Canadian provinces. CMAJ. 2001; 165(3):277-83. PMC: 81326. View

Oseni T, Zhang B, Coopey S, Gadd M, Hughes K, Chang D . Twenty-Five Year Trends in the Incidence of Ductal Carcinoma in Situ in US Women. J Am Coll Surg. 2019; 228(6):932-939. DOI: 10.1016/j.jamcollsurg.2019.01.018. View

van Seijen M, Lips E, Thompson A, Nik-Zainal S, Futreal A, Hwang E . Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 2019; 121(4):285-292. PMC: 6697179. DOI: 10.1038/s41416-019-0478-6. View

Elshof L, Schmidt M, Rutgers E, van Leeuwen F, Wesseling J, Schaapveld M . Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. Ann Surg. 2017; 267(5):952-958. PMC: 5916471. DOI: 10.1097/SLA.0000000000002239. View

Koh V, Lim J, Thike A, Cheok P, Thu M, Tan V . Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients. Breast Cancer Res Treat. 2015; 152(2):293-304. DOI: 10.1007/s10549-015-3472-6. View

Narod S, Iqbal J, Giannakeas V, Sopik V, Sun P . Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ. JAMA Oncol. 2015; 1(7):888-96. DOI: 10.1001/jamaoncol.2015.2510. View

Kerlikowske K, Molinaro A, Cha I, Ljung B, Ernster V, Stewart K . Characteristics associated with recurrence among women with ductal carcinoma in situ treated by lumpectomy. J Natl Cancer Inst. 2003; 95(22):1692-702. DOI: 10.1093/jnci/djg097. View

Ryser M, Weaver D, Zhao F, Worni M, Grimm L, Gulati R . Cancer Outcomes in DCIS Patients Without Locoregional Treatment. J Natl Cancer Inst. 2019; 111(9):952-960. PMC: 6748726. DOI: 10.1093/jnci/djy220. View

10.

Sanders M, Schuyler P, Dupont W, Page D . The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005; 103(12):2481-4. DOI: 10.1002/cncr.21069. View

11.

Bijker N, Donker M, Wesseling J, den Heeten G, Rutgers E . Is DCIS breast cancer, and how do I treat it?. Curr Treat Options Oncol. 2012; 14(1):75-87. DOI: 10.1007/s11864-012-0217-1. View

12.

Curigliano G, Burstein H, Winer E, Gnant M, Dubsky P, Loibl S . De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017; 28(8):1700-1712. PMC: 6246241. DOI: 10.1093/annonc/mdx308. View

13.

Emdin S, Granstrand B, Ringberg A, Sandelin K, Arnesson L, Nordgren H . SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006; 45(5):536-43. DOI: 10.1080/02841860600681569. View

14.

Julien J, Bijker N, Fentiman I, Peterse J, Delledonne V, Rouanet P . Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. Lancet. 2000; 355(9203):528-33. DOI: 10.1016/s0140-6736(99)06341-2. View

15.

Houghton J, George W, Cuzick J, Duggan C, Fentiman I, Spittle M . Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003; 362(9378):95-102. DOI: 10.1016/s0140-6736(03)13859-7. View

16.

Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W . Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998; 16(2):441-52. DOI: 10.1200/JCO.1998.16.2.441. View

17.

Wapnir I, Dignam J, Fisher B, Mamounas E, Anderson S, Julian T . Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst. 2011; 103(6):478-88. PMC: 3107729. DOI: 10.1093/jnci/djr027. View

18.

Hughes L, Wang M, Page D, Gray R, Solin L, Davidson N . Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2009; 27(32):5319-24. PMC: 2773217. DOI: 10.1200/JCO.2009.21.8560. View

19.

Solin L, Gray R, Hughes L, Wood W, Lowen M, Badve S . Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. J Clin Oncol. 2015; 33(33):3938-44. PMC: 4652014. DOI: 10.1200/JCO.2015.60.8588. View

20.

Smith G, Smith B, Haffty B . Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys. 2006; 65(5):1397-403. DOI: 10.1016/j.ijrobp.2006.03.009. View